Bright Light Therapy for Sleep Disturbance in People With Multiple Scl
Bright Light Therapy for Sleep Disturbance in People With Multiple Sclerosis
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Light therapy
What it measured
Main measures
Number of adverse events
2 weeks
Safety
Other measures (6)
Change in sleep quantity as assessed by the Pittsburgh Sleep Quality Index (PSQI)
Baseline, 2 weeks
Mood and sleepChange in sleep efficiency as assessed by the Pittsburgh Sleep Quality Index (PSQI)
Baseline, 2 weeks
Mood and sleepChange in overall sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI)
Baseline, 2 weeks
Mood and sleepChange in insomnia severity as assessed by the Insomnia Severity Index (ISI)
Baseline, 2 weeks
Mood and sleepChange in daytime sleepiness as assessed by the Epworth Sleepiness Scale (ESS)
Baseline, 2 weeks
Mood and sleepChange in fatigue severity as assessed by the Neuro-QoL fatigue questionnaire
Baseline, 2 weeks
FatigueQuality of life (reported by participants)
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* Diagnosis of MS * Evidence of sleep disturbance * Stable on immunomodulatory MS therapy or no therapy for at least 6 months prior to study initiation * Stable on antidepressants for at least 3 months prior to study initiation and no evidence * Stable on fatigue medication for at least 3 months prior to study initiation * Willing and able to provide informed consent and follow study procedures.
Exclusion criteria
* Evidence of cognitive impairment * Low risk for sleep disordered breathing * Other comorbid ophthalmologic disorders (e.g. cataracts, glaucoma, blindness) * Traveled across two time zones within 90 days of study screening. * Not participating in shift work * MS relapse or history of acute optic neuritis within 30 days * No prior history of bipolar disorder * No evidence of current depression * Diagnosis of severe periodic limb movement disorder or severe restless legs syndrome
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Sleep disturbance is common in people with multiple sclerosis (MS) and contributes to diminished quality of life. Bright light therapy may be an innovative strategy to reduce sleep disturbance in MS, possibly through its effects on a subtype of retinal ganglion cells that help regulate circadian rhythms and sleep. This pilot study will evaluate whether, in people with MS, bright light therapy reduces sleep disturbance and explore whether light therapy improves function of these cells.
Loading reviews and guidelines…
History
Started
Feb 2021
Main results due
Dec 2025
Finished
Jan 2026